CSF2 and non-Hodgkin lymphoma: Up to now, chemotherapy + sargramostim in the treatment of Acute Myelogenous Leukemia and sargramostim after autologous and allogenic BMT in Non-Hodgkin’s lymphoma (NHL), acute lymphoblastic leukemia (ALL) and Hodgkin’s disease are approved by FDA.1016 Similar to Sargramostim, Molgramostim is a recombinant GM-CSF that acts as an immunostimulatory.